Although rare, 3p microdeletion cases have been well described in the clinical literature. The clinical phenotype includes; intellectual disability (ID), growth retardation, facial dysmorphism, and cardiac malformations. Advances in chromosome microarray (CMA) testing narrowed the 3p25 critical region to a 124 kb region, and recent Whole Exome Sequencing (WES) studies have suggested that the SETD5 gene contributes significantly to the 3p25 phenotype. Loss-of-Function (LoF) variants in SETD5 are now considered a likely cause of ID. We report here a patient with a frameshift LoF variant in exon 12 of SETD5. This patient has features overlapping with other patients described with LoF SETD5 variants to include; similar facial morphology, feeding difficulties, ID, behavioral abnormalities and leg length discrepancy. In addition, he presents with an aberrant blind ending bronchus. This report adds to publications describing intragenic mutations in SETD5 and supports the assertion that de novo LoF mutations in SETD5 present with an overlapping but distinct phenotype in comparison with 3p25 microdeletion syndromes.
K E Y W O R D S
3p microdeletion, 3p25, SETD5, aberrant blind ending bronchus, intellectual disability, loss of function 1 | INTRODUCTION Intellectual Disability (ID) has a worldwide prevalence of approximately 1-3% and has become the most frequent reason for referral to paediatric genetic services (Maulik & Darmstadt, 2007) . Due to its clinical and genetic heterogeneity, the underlying cause for ID remains unclear. However, advances in genetic testing have led to the elucidation of several novel genes linked to ID, some of the most successful studies have led to the identification of de novo LoF sequence variants in candidate genes (De Ligt et al., 2012; Rauch et al., 2012; Vissers et al., 2010) .
Distal deletions of the short arm of chromosome 3 were first characterized by cytogenetic and FISH analysis (Aqua et al., 1995; Verjaal & De Nef, 1978) . This condition results in a well-described syndrome associated with a clinical phenotype that includes; ID, growth retardation, facial dysmorphism, and cardiac malformations.
The severity of the condition varies considerably, with the size of the deletion apparently correlating with the severity of the phenotype (Drumheller et al., 1996) .
A report by Kellogg, Sum, and Wallerstein (2013) described four patients with 3p25.3 deletions and ID, including three previously reported patients by Peltekova, Macdonald, and Armour (2012), Riess et al. (2012) , and Gunnarsson and Foyn Bruun (2010) . These 3p25.3 deletion carriers had a narrow range of overlap comprising of three genes including SETD5. In addition to ID, patients had a common phenotype of depressed nasal bridge (3/4), low set ears (3/4), and philtrum differences (3/4). Other features were more variable including; cardiac malformations (2/4), ptosis (2/4), low birth The only published cases of an inherited SETD5 variant suggested a more variable phenotype. Two siblings with developmental delay and features consistent with previously reported SETD5 de novo cases were compared to their father who had only mild intellectual impairment with some features of SETD5. These patients did not have ritualized behavior or autism, abnormalities in eye structure, gastrointestinal, and/or abdominal wall defects or scoliosis/kyphosis (Szczałuba et al., 2016) .
Frequency data for SETD5 mutations is difficult to obtain. However, the genetic database Decipher includes 34 patients with SETD5 sequence variants (https://decipher.sanger.ac.uk/), the SFARI database of genes linked with autism has 47 SETD5 mutations reported in its human gene module (https://sfari.org/) and a recent large study of 4,293 patients recruited from the Deciphering Developmental Disorders (DDD) study identified 17 patients with de novo SETD5 mutations (Deciphering Developmental Disorders, 2017) . SETD5 is, therefore, likely one of the most commonly mutated genes in developmental disorders (DECIPHER 2009; Deciphering Developmental Disorders, 2017) .
Adding to published reports, we present a patient with a de novo heterozygous c.1381_1388del, p.(Asn461 fs) frameshift mutation in exon 12 of SETD5, who also has an aberrant blind ending bronchus, thus expanding the phenotype.
| MATERIALS AND METHODS
This patient was recruited to the Deciphering Developmental Disorders (DDD) study. Trio-based exome sequencing was performed on the affected individual and their parents, as previously described (Wright et al., 2014) . Each affected individual also had a highresolution analysis for copy number abnormalities using array-based comparative genomic hybridization (aCGH). Putative de novo mutations were identified from exome data using DeNovoGear software (Ramu et al., 2013) and were validated using targeted Sanger sequencing. Mutation nomenclature is according to HGVS guidelines with reference transcript NM_001080517.2.
| CLINICAL REPORT
This patient is the second child of healthy non-consanguineous, White
European parents with unremarkable family history. He was born at term with a birth weight of 2.976 kg, following an uneventful pregnancy. Raised alpha fetoprotein (AFP) levels were noted but antenatal scans were normal. There were no postnatal complications.
Failure to thrive and difficulty gaining weight were noted and he later required fundoplication. He was born with postaxial polydactyly in all extremities requiring surgical removal at the age of 4 months and tongue tie. Persistent cough was noted at age 2 days and recurrent infections have continued to affect him, with a later diagnosis of asthma. His chest infections were thought to be due to an aberrant blind ending bronchus identified on bronchoscopy. There were no concerns with his vision but conductive hearing loss was treated with grommet insertion.
Developmentally, at 10 months he could not sit unaided, he walked at 23 months. Leg asymmetry was detected subsequently. His first word was at 13 months, with a vocabulary of single words at 2 years. At a clinical psychologist assessment at 5½ years old, a Verbal IQ of 83 (13th percentile) and Performance IQ of 98 (45th percentile) were recorded. Assessment also showed some weakness in social communication and a stutter with recurrent dribbling. However, he did not fulfil criteria for diagnosis of Autism Spectrum Disorder. At age 7, he was attending mainstream school with additional support. He was reported at school to have a dyslexic profile with "low average" level. In terms of behavior, repetitive stereotyped behaviors were noted such as repeatedly touching his face. He was late to develop imaginary play and weakness in social interaction with peers was noted. Reassessment at age 9 highlighted his complex communication needs and problems acquiring language skills. 
| DISCUSSION
The 3p critical region was initially thought to be a 3-5 Mb region (Aqua et al., 1995) . Subsequent patients were described with narrow overlapping regions (Gunnarsson & Foyn Bruun, 2010; Kellogg et al., 2013; Peltekova et al., 2012; Riess et al., 2012) and SETD5 was considered to be the strongest candidate gene (Peltekova et al., 2012; Shuib et al., 2009) . Further evidence to support pathogenicity of SETD5, came from large cohorts of de novo mutation carriers (Deciphering Developmental Disorders, 2017; Iossifov et al., 2014; Pinto et al., 2016; Rauch et al., 2012) .
The coding sequence of SETD5 is 4,329 bp long and encodes 1,442 amino acids. It is ubiquitously expressed and high levels have been seen in the cerebral cortex, the intestine, and the eye (Kuechler et al., 2015; Nagase et al., 1997) . The gene is highly evolutionarily conserved suggesting that it is functionally important and is considered a member of the "writers" group of epigenetic genes (Kleefstra et al., 2006) .
In silico domain analysis has showed that SETD5 is a multidomain protein containing a SET domain and a putative PHD domain (Kuechler et al., 2015) . It thought have an important role in cell replication and gene expression through regulation of histone acetylation (Hu et al., 2010; Jones et al., 2008; Tanaka et al., 2000; Yao et al., 1998) . Genes encoding histone modifiers are increasingly recognized to have a contribution to ID (Berdasco & Esteller, 2013 ).
Animal models have demonstrated that SETD5 is important in mammalian development with SETD5 deficient mouse embryos exhibiting severe developmental delay, vascular abnormalities, apoptosis, and reduced cellular proliferation; findings consistent with impairment of gene expression (Osipovich, Gangula, Vianna, & Magnuson, 2016) .
Histone modifier genes are all dosage sensitive and haploinsufficiency is believed to be the disease mechanism. In vitro analysis has shown that variants in SETD5 trigger nonsense mediated decay (NMD) pointing to LoF (Kuechler et al., 2015) . Haploinsufficiency of a single gene has also proven to be casual for the specific phenotype in a number of microdeletion syndromes. There are several examples of this including; EHMT1 in association with 9q34 deletion and SATB2 in association with 2q33.1 deletion.
The phenotypic features of our patient with a de novo SETD5 variant fit with previously described patients to include; ID, language delay, ritualized behavior, feeding difficulties, abnormal ears, 
